This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lipman, J.
Right arrow Articles by Rickard, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lipman, J.
Right arrow Articles by Rickard, C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 1999, p. 2559-2561, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Low Plasma Cefepime Levels in Critically Ill Septic Patients: Pharmacokinetic Modeling Indicates Improved Troughs with Revised Dosing

J. Lipman,1,2,* S. C. Wallis,1 and C. Rickard2

Division of Anaesthesiology and Intensive Care, University of Queensland,1 and Intensive Care Facility, Royal Brisbane Hospital,2 Brisbane, Queensland, Australia

Received 1 February 1999/Returned for modification 15 May 1999/Accepted 22 August 1999

The pharmacokinetics of a 2-g bolus of cefepime were measured in critically ill patients with normal renal function. Variable and low trough plasma drug concentrations were found, and 8 of 10 patients had levels below the MIC at which 50% of the isolates are inhibited for Pseudomonas aeruginosa. Computer simulations predicted that continuous infusion and shorter dosing intervals would increase trough levels.

* Corresponding author. Mailing address: Intensive Care Facility, Royal Brisbane Hospital, Herston Rd. 4029, Brisbane, Queensland, Australia. Phone: 61 7 3253-8897. Fax: 61 7 3253 3542. E-mail: jlipman{at}gasbone.herston.uq.edu.au.

Antimicrobial Agents and Chemotherapy, October 1999, p. 2559-2561, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Nicasio, A. M., Ariano, R. E., Zelenitsky, S. A., Kim, A., Crandon, J. L., Kuti, J. L., Nicolau, D. P. (2009). Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically Ill Patients with Ventilator-Associated Pneumonia. Antimicrob. Agents Chemother. 53: 1476-1481 [Abstract] [Full Text]  
  • Roos, J. F., Bulitta, J., Lipman, J., Kirkpatrick, C. M. J. (2006). Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 58: 987-993 [Abstract] [Full Text]  
  • Koenig, S. M., Truwit, J. D. (2006). Ventilator-Associated Pneumonia: Diagnosis, Treatment, and Prevention. Clin. Microbiol. Rev. 19: 637-657 [Abstract] [Full Text]  
  • Navas, D., Caillon, J., Gras-Le Guen, C., Jacqueline, C., Kergueris, M.-F., Bugnon, D., Potel, G. (2004). Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics. J Antimicrob Chemother 54: 767-771 [Abstract] [Full Text]  
  • Lipman, J., Wallis, S. C., Boots, R. J. (2003). Cefepime Versus Cefpirome: The Importance of Creatinine Clearance. Anesth. Analg. 97: 1149-1154 [Abstract] [Full Text]  
  • Tam, V. H., McKinnon, P. S., Akins, R. L., Drusano, G. L., Rybak, M. J. (2003). Pharmacokinetics and Pharmacodynamics of Cefepime in Patients with Various Degrees of Renal Function. Antimicrob. Agents Chemother. 47: 1853-1861 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»